News
According to Benzinga Pro, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.13 ...
Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...
StockStory.org on MSN6d
Exact Sciences (EXAS) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.
Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...
Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...
Zacks.com on MSN4d
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...
Review the current Regeneron Pharmaceuticals Inc (REGN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if REGN is the best investment for you.
4d
Earnings live: Snap stock plunges, Disney beats, Uber announces buybacks, McDonald's sales rebound
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback